Neurocrine Biosciences, Inc.(NBIX)NASDAQ
Stock Performance & Returns
Peer Comparison
Relative scale, growth, and profitability vs sector peers
| Ticker | Market Cap | P/E Ratio | Revenue Growth | Net Margin | EPS | ROE | Debt/Equity | Dividend Yield | 52W High | 52W Low |
|---|---|---|---|---|---|---|---|---|---|---|
NBIX | 16.10 B | 23.15x | 39.50% | 20.91% | $6.84 | 22.09% | 0.13 | - | $186.12 | $122.14 |
MRNA | 59.43 B | -18.66x | 2.10% | -1.41% | $-7.98 | -39.00% | 0.19 | - | $176.66 | $22.28 |
INSM | 27.66 B | -29.88x | 2.96% | -76.94% | $-4.24 | -87.22% | 0.98 | - | $212.75 | $90.39 |
INCY | 25.95 B | 16.31x | 37.70% | 27.71% | $7.85 | 30.67% | 0.60 | - | $132.60 | $81.09 |
UTHR | 21.03 B | 17.56x | -1.90% | 41.56% | $27.92 | 19.32% | - | - | $609.35 | $375.61 |
Peer Valuation & Performance Analysis
Peer group analysis for Neurocrine Biosciences, Inc. (NBIX) compared to its primary competitors (including MRNA, INSM, INCY) reveals distinct metrics. NBIX trades at a valuation premium compared to its competitors, with a P/E ratio of 23.2x versus the peer average of -3.7x (representing a -731% premium). This indicates that the market expects superior growth or commands a quality premium for NBIX. In terms of growth, NBIX's revenue growth of 39.5% exceeds the peer average of 10.2%, highlighting its competitive strength and market share gains. Additionally, it boasts superior profitability with a net margin of 20.9% compared to the peer average of -2.3%, demonstrating strong cost controls and pricing power.
Peer Performance Rankings
Ranking comparison across key performance metrics
P/E Ratio (Lower is Better)
Revenue Growth
Net Profit Margin
Financial Rankings Summary
• NBIX ranks #3 in P/E ratio, #1 in revenue growth, and #3 in profit margins
• Average ranking: #2 - 🎯 Top-tier fundamentals relative to peer group
• Rankings based on actual financial data from company reports
Historical Trading Data
Price and volume data with customizable timeframes
Showing 15 of 15 trading sessions from the last 15 days
| Date | Open | High | Low | Close | Volume | Daily Change |
|---|---|---|---|---|---|---|
| 2026-09-03 | $159.93 | $159.93 | $156.76 | $158.35 | 758,300 | -0.99% |
| 2026-09-02 | $157.39 | $160.43 | $155.09 | $157.79 | 1,037,900 | +0.25% |
| 2026-09-01 | $154.31 | $157.03 | $153.70 | $156.76 | 878,400 | +1.59% |
| 2026-08-31 | $153.11 | $155.00 | $151.77 | $154.03 | 1,741,100 | +0.60% |
| 2026-08-28 | $155.92 | $156.57 | $153.08 | $154.06 | 813,000 | -1.19% |
| 2026-08-27 | $155.28 | $156.75 | $154.61 | $155.92 | 730,300 | +0.41% |
| 2026-08-26 | $153.21 | $159.40 | $152.02 | $156.59 | 1,119,100 | +2.21% |
| 2026-08-25 | $153.84 | $156.13 | $152.01 | $153.37 | 1,041,800 | -0.31% |
| 2026-08-24 | $152.57 | $154.56 | $151.77 | $153.04 | 1,207,500 | +0.31% |
| 2026-08-21 | $153.13 | $155.27 | $152.51 | $152.57 | 1,227,600 | -0.37% |
| 2026-08-20 | $154.99 | $155.81 | $152.50 | $152.93 | 870,700 | -1.33% |
| 2026-08-19 | $156.56 | $156.56 | $154.34 | $155.54 | 1,162,800 | -0.65% |
| 2026-08-18 | $155.92 | $156.24 | $153.46 | $154.23 | 1,037,500 | -1.08% |
| 2026-08-17 | $151.62 | $154.81 | $150.69 | $154.49 | 1,169,000 | +1.89% |
| 2026-08-14 | $149.72 | $153.42 | $148.78 | $152.72 | 1,305,100 | +2.00% |
Explore More Analysis for NBIX
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.